Company Overview and News
It was a week where oil prices extended their recent declines but natural gas futures moved above the critical $3 threshold.
XOM EEXXQ VLO MPC EXXI NEE.PRI BHI NEE.PRJ EGC EXXIQ NEE.PRC EXIXQ CVX NEE.PRQ NEE.PRR RIG PAA NEE SGAZF
Transocean Ltd. (RIG - Free Report) recently announced its intention to retire four of its aging rigs —Deepwater Discovery, Deepwater Frontier, Deepwater Millennium and Songa Trym — amid continued offshore weakness. Post the announcement of its decision, the company’s shares have declined more than 3% to eventually close at $11.92 on Jun 15. In regard to this, the oilfield services player will book non-cash impairment charges of around $520 million, which will be reflected in its second-quarter results.
ESV SDRL RIG PES SGAZF
NEW YORK, June 11 — A hedge fund run by a former associate of billionaire John Fredriksen has gained 69 per cent in two years betting on shunned oil-related assets — and it’s not nearly done exploiting the recovery.
ETP.PRC SLB ETP ESV SCL SLB RIG SGAZF
In recent months, I’ve been often asked about when Seadrill (SDRL) will emerge from Chapter 11. Prior to June 7, 2018, we only had a vague timeline for this event so such a question could not have been answered. Now, we have an official announcement from the company.
NE ESV NOBGF N21 NOBGY SDRL DTK RIG
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to RIG / Transocean, Inc. on message board site Silicon Investor.
as of ET